28.6 C
Comune di Monopoli
martedì 22 Giugno 2021

Prosit Sole Biotechnology Initiates First-In-Human Clinical Trial of Novel Interferon Lambda Chimera in US

Da leggere

BALTIMORE, May 26, 2021 /PRNewswire/ — Prosit Sole Biotechnology, a clinical-stage biotech company developing novel protein therapeutics, today announces that it has initiated the first-in-human (“FIH”) Phase I clinical trial of PSP001 in US. PSP001 is a novel, long acting and potent interferon lambda chimera injection. The first dose was administered on May 25, 2021. 

Type III interferons (IFN’s), also termed interferon lambda’s (IFNλ’s) constitute a new addition to the IFN family. Their unique receptor IFNλR1 is particularly abundant at the barrier surfaces, such as the respiratory tracts, the gastrointestinal tracts, and the liver. Non-redundant to type I interferons (IFNα and IFNβ), IFNλ’s exhibit unique antiviral and immune modulatory activities. Prosit Sole Biotechnology is developing PSP001 for the treatment of chronic norovirus enteritis in hematopoietic and solid organ transplant recipients.  

“Chronic norovirus enteritis in immunocompromised patients is an urgent unmet medical need. There are no approved therapies for this debilitating disease.” said Hongyu Liu, PhD, CEO of Prosit Sole Biotechnology. “We are also actively developing PSP001 for additional indications such as chronic hepatitis B.”  

Investor Contact: 

Email: liuhongyu@prositsole.com

Media Contact: 

Cindy YuEmail: cindy.yu@prositsole.com010-62975234 

Source: Prosit Sole Biotechnology 

To learn more, please visit http://www.prositsole.com/



Per favore inserisci il tuo commento!
Per favore inserisci il tuo nome qui

Questo sito usa Akismet per ridurre lo spam. Scopri come i tuoi dati vengono elaborati.

Ultime news

Mascherine all’aperto zona bianca, Cts e governo: stop obbligo da 28 giugno

Stop all’obbligo di mascherine all’aperto a partire dal 28 giugno, lunedì prossimo, quando tutte le regioni saranno in zona...

Potrebbe interessarti